SAN FRANCISCO (MedPage Today) -- Second-line therapy combining ramucirumab with best supportive care significantly improved overall and progression-free survival in patients with metastatic gastric adenocarcinoma, researchers reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment